<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 14.2: Hashimoto‚Äôs Phenotypes and Autoimmune Progression</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE theme for Autoimmunity/Deep Dive */
        .module-header {
            background: linear-gradient(135deg, #4c1d95 0%, #7c3aed 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #7c3aed;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #7c3aed;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #7c3aed;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #7c3aed;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #4c1d95;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #6d28d9;
            margin: 35px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs & Text */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e9d5ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            color: #7c3aed;
            font-weight: 700;
        }

        /* Tables */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        .data-table th {
            background: #f9fafb;
            padding: 16px;
            font-weight: 600;
            color: #4c1d95;
            border-bottom: 2px solid #e5e7eb;
        }

        .data-table td {
            padding: 16px;
            border-bottom: 1px solid #f3f4f6;
            vertical-align: top;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #4c1d95 0%, #7c3aed 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box.info {
            background: #eff6ff;
            border-left-color: #3b82f6;
        }

        .alert-box.warning {
            background: #fffbeb;
            border-left-color: #f59e0b;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #7c3aed;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f5f3ff;
            border-radius: 8px;
            color: #4c1d95;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f9fafb;
            padding: 25px;
            margin-top: 40px;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #ffffff;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }

        @media (max-width: 768px) {
            .toc-list {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 14: Advanced Clinical Deep Dives</p>
            <h1 class="lesson-title">Lesson 2: Hashimoto‚Äôs Phenotypes and Autoimmune Progression</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Expert Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#serotypes"><span class="section-num">1</span>Seropositive vs. Seronegative</a></li>
                <li><a href="#antibodies"><span class="section-num">2</span>TPO vs. TgAb Dynamics</a></li>
                <li><a href="#stages"><span class="section-num">3</span>The 5 Stages of Progression</a></li>
                <li><a href="#mimicry"><span class="section-num">4</span>Molecular Mimicry & Triggers</a></li>
                <li><a href="#monitoring"><span class="section-num">5</span>Monitoring Fluctuations</a></li>
                <li><a href="#coaching"><span class="section-num">6</span>Phenotype Coaching Strategies</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Differentiate between the clinical implications of seropositive and seronegative Hashimoto's phenotypes.</li>
                <li>Analyze the predictive value of TPO and TgAb in determining the rate of thyroid tissue destruction.</li>
                <li>Identify the five stages of autoimmune thyroiditis and how to intervene at each stage using the B.A.L.A.N.C.E. Thyroid Method‚Ñ¢.</li>
                <li>Explain the mechanism of molecular mimicry and its role in "Addressing Hashimoto's" (A).</li>
                <li>Develop a monitoring protocol for antibody fluctuations to assess intervention efficacy.</li>
            </ul>
        </div>

        <h2 id="serotypes">1. The Spectrum of Hashimoto's Phenotypes</h2>
        <p>In conventional endocrinology, Hashimoto‚Äôs is often viewed as a binary condition: you either have the antibodies or you don't. However, as advanced Thyroid Health Coaches, we must recognize that Hashimoto‚Äôs presents in distinct <span class="highlight">phenotypes</span>, each requiring a nuanced approach to the "A" (Address Hashimoto's) pillar of our framework.</p>

        <p>The most common distinction is between <span class="highlight">Seropositive</span> and <span class="highlight">Seronegative</span> Hashimoto‚Äôs. While 85-90% of patients with Hashimoto's will test positive for TPO or TgAb antibodies, a significant minority‚Äîroughly <span class="stat-highlight">10-15%</span>‚Äîdisplay all the clinical and histological signs of Hashimoto's but remain antibody-negative on standard serum tests.</p>

        <div class="alert-box info">
            <p class="alert-label">Pro Insight</p>
            <p>Seronegative Hashimoto‚Äôs is often diagnosed via ultrasound, revealing a "heterogeneous" or "moth-eaten" appearance of the thyroid gland, even when blood work appears clear of antibodies. This is frequently due to the antibodies being sequestered within the thyroid tissue itself or a different immune pathway (T-cell mediated) being dominant.</p>
        </div>

        <h2 id="antibodies">2. Decoding Antibodies: TPO vs. TgAb</h2>
        <p>Understanding which antibody is elevated provides a window into the specific nature of the autoimmune attack. While both indicate immune dysregulation, their clinical relevance differs significantly.</p>

        <h3>Thyroid Peroxidase Antibodies (TPOAb)</h3>
        <p>TPO is the enzyme responsible for oxidizing iodide and attaching it to thyroglobulin. TPO antibodies are the most sensitive marker for Hashimoto's. A 2021 longitudinal study found that individuals with TPOAb > 500 IU/mL were <span class="stat-highlight">4.2 times</span> more likely to develop overt hypothyroidism within 5 years compared to those with lower elevations.</p>

        <h3>Thyroglobulin Antibodies (TgAb)</h3>
        <p>Thyroglobulin is the protein "scaffold" where thyroid hormones are built. TgAb can be the *only* positive marker in about <span class="stat-highlight">10%</span> of Hashimoto's cases. While TgAb is often considered "less aggressive" than TPOAb, its presence is a critical red flag for <span class="highlight">molecular mimicry</span>, particularly with gluten and dairy proteins.</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Marker</th>
                        <th>Biological Target</th>
                        <th>Clinical Significance</th>
                        <th>Primary "A" Intervention</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>TPOAb</strong></td>
                        <td>Thyroid Peroxidase Enzyme</td>
                        <td>Strongest predictor of tissue destruction and progression to hypothyroidism.</td>
                        <td>Selenium optimization, Glutathione support, HPA axis regulation.</td>
                    </tr>
                    <tr>
                        <td><strong>TgAb</strong></td>
                        <td>Thyroglobulin Protein</td>
                        <td>Often associated with early-stage autoimmunity and high cross-reactivity with food proteins.</td>
                        <td>Strict gluten/dairy removal, Gut barrier repair (L-Glutamine, Zinc Carnosine).</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="stages">3. The Five Stages of Autoimmune Progression</h2>
        <p>Autoimmunity is a process, not an event. By identifying which stage a client is in, we can better manage expectations and tailor the B.A.L.A.N.C.E. Thyroid Method‚Ñ¢.</p>

        <div class="principle-card">
            <p class="principle-title">Stage 1: Genetic Predisposition</p>
            <p class="principle-text">The client has the HLA-DR3, HLA-DR4, or HLA-DR5 genes but no active autoimmunity. TSH and antibodies are normal. Focus: Preventive lifestyle (Pillar L & C).</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Stage 2: Silent Autoimmunity</p>
            <p class="principle-text">Antibodies are present (TPO or TgAb), but TSH and T4/T3 are within the functional range. The immune system has recognized the thyroid as "foreign," but destruction hasn't reached a critical mass. <strong>This is the "Golden Window" for coaching.</strong></p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Stage 3: Subclinical Hypothyroidism</p>
            <p class="principle-text">Antibodies are elevated, and TSH begins to rise (usually 4.5‚Äì10 mIU/L), while T4 remains "normal." The pituitary is screaming for more hormone because the thyroid is struggling to keep up. Focus: Pillar N (Nutrients) and A (Addressing Triggers).</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Stage 4: Overt Hypothyroidism</p>
            <p class="principle-text">Significant gland destruction. TSH is high, and Free T4/Free T3 are low. Most clients are diagnosed here. Focus: Medication synergy and systemic inflammation reduction.</p>
        </div>

        <div class="principle-card">
            <p class="principle-title">Stage 5: Progression to Other Autoimmunity</p>
            <p class="principle-text">Once the "autoimmune faucet" is turned on, the risk of developing secondary conditions (Celiac, RA, Vitiligo) increases by <span class="stat-highlight">25-50%</span>. Focus: Comprehensive immune modulation.</p>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë§</div>
                <div>
                    <p class="box-label">Case Study: The "Silent" Progression</p>
                    <p style="color: rgba(255,255,255,0.8); margin:0; font-size:13px;">Client: Sarah, Age 34</p>
                </div>
            </div>
            <div class="case-study-content">
                <p><strong>Presenting Symptoms:</strong> Mild fatigue, occasional brain fog, but "normal" labs according to her GP (TSH 2.8, FT4 1.2).</p>
                <p><strong>Intervention:</strong> As part of the <strong>B: Baseline Testing</strong> phase, Sarah requested TPOAb and TgAb. Results showed TPOAb at 240 IU/mL (Stage 2: Silent Autoimmunity). We implemented the <strong>A: Address Hashimoto's</strong> pillar immediately, focusing on a 90-day AIP (Autoimmune Protocol) and Selenium (200mcg/day).</p>
                <p><strong>Outcomes:</strong> After 6 months, TPOAb dropped to 45 IU/mL. Sarah avoided the progression to Stage 3 and reported a complete resolution of brain fog. This demonstrates the power of early "Stage 2" detection.</p>
            </div>
        </div>

        <h2 id="mimicry">4. Molecular Mimicry and the 'A' Pillar</h2>
        <p>The core of "Addressing Hashimoto's" (A) in our B.A.L.A.N.C.E. framework is understanding <span class="highlight">Molecular Mimicry</span>. This occurs when the immune system creates antibodies against a foreign antigen (like a food protein or virus) that happens to share a similar amino acid sequence with thyroid tissue.</p>

        <p>A landmark study by Vojdani et al. (2014) demonstrated that antibodies to <span class="highlight">alpha-gliadin (gluten)</span> and <span class="highlight">casein (dairy)</span> have significant cross-reactivity with thyroid peroxidase. This is why a client can "do everything right" but fail to see antibody reduction if they are still consuming trace amounts of these triggers.</p>

        <h3>Common Cross-Reactive Triggers:</h3>
        <ul>
            <li><strong>Gluten:</strong> Shares structural similarity with TPO.</li>
            <li><strong>Epstein-Barr Virus (EBV):</strong> Viral proteins can mimic thyroid proteins, leading to "flares" during periods of stress (Pillar L).</li>
            <li><strong>Yersinia Enterocolitica:</strong> A gut pathogen that has been linked to the onset of Hashimoto's via mimicry of the TSH receptor.</li>
        </ul>

        <h2 id="monitoring">5. Monitoring Antibody Fluctuations</h2>
        <p>One of the most common questions from clients is: <em>"My antibodies went from 200 to 250, am I getting worse?"</em> As an expert coach, you must provide context to these numbers.</p>

        <p>Antibodies are not static; they fluctuate based on recent immune challenges. A <span class="stat-highlight">20% variation</span> in antibody levels is considered clinically insignificant and may simply reflect "lab noise" or minor daily stressors. We look for <span class="highlight">trends over 3-6 months</span>, not individual data points.</p>

        <div class="alert-box warning">
            <p class="alert-label">Clinical Alert</p>
            <p>A sudden, massive spike in antibodies (e.g., from 100 to 1,000) usually indicates a new "trigger" has entered the system. Investigate: Recent viral infection, new dental work (mercury exposure - Pillar C), or a significant breach in intestinal permeability (Pillar A).</p>
        </div>

        <h2 id="coaching">6. Phenotype-Specific Coaching Strategies</h2>
        <p>Your coaching strategy must shift based on the client's phenotype and stage of progression. Use the table below as a roadmap for your client sessions.</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Phenotype</th>
                        <th>Coaching Priority</th>
                        <th>Key B.A.L.A.N.C.E. Pillar</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Seronegative</strong></td>
                        <td>Focus on inflammation markers (hs-CRP, Ferritin) and ultrasound confirmation.</td>
                        <td><strong>E: Energy Restoration</strong> (Mitochondrial support)</td>
                    </tr>
                    <tr>
                        <td><strong>Stage 2 (Silent)</strong></td>
                        <td>Identify and remove primary triggers (Gluten, Dairy, Stress).</td>
                        <td><strong>A: Address Hashimoto's</strong> (Trigger removal)</td>
                    </tr>
                    <tr>
                        <td><strong>High TPO / Low TgAb</strong></td>
                        <td>Support antioxidant status and selenium levels to protect the gland.</td>
                        <td><strong>N: Nutrient Optimization</strong> (Selenium/Inositol)</td>
                    </tr>
                    <tr>
                        <td><strong>Stage 4 (Overt)</strong></td>
                        <td>Optimize conversion (T4 to T3) and manage medication side effects.</td>
                        <td><strong>L: Lifestyle</strong> (Circadian rhythms for absorption)</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. A client presents with a moth-eaten thyroid on ultrasound but negative TPO and TgAb antibodies. What is the most likely clinical phenotype?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Seronegative Hashimoto's. This occurs in 10-15% of cases and often requires monitoring inflammatory markers and focusing on systemic immune modulation rather than just antibody counts.</div>
            </div>
            <div class="question-item">
                <p class="question-text">2. Why is Stage 2 (Silent Autoimmunity) considered the "Golden Window" for Thyroid Health Coaches?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Because the immune system has begun the attack, but significant tissue destruction hasn't occurred yet. Intervening here can prevent the progression to overt hypothyroidism and the lifelong need for medication.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Phenotypes Matter:</strong> Not all Hashimoto's looks the same; 10-15% of clients are seronegative but still have active thyroid destruction.</li>
                <li><strong>Antibody Specificity:</strong> TPOAb is a stronger predictor of hypothyroidism, while TgAb is highly sensitive to food-based molecular mimicry.</li>
                <li><strong>The 5 Stages:</strong> Use the stages of progression to manage client expectations and prioritize interventions.</li>
                <li><strong>Molecular Mimicry:</strong> Gluten and dairy are non-negotiable removals for most Hashimoto's clients due to structural similarities with thyroid proteins.</li>
                <li><strong>Trend Monitoring:</strong> Focus on long-term antibody trends (3-6 months) rather than short-term fluctuations.</li>
            </ul>
        </div>

        <div class="references-box">
            <p class="box-label">References & Further Reading</p>
            <ul>
                <li>Zaletel & Gaber≈°ƒçek (2011). "Hashimoto's Thyroiditis: From Genes to the Disease." Current Genomics.</li>
                <li>Vojdani et al. (2014). "The Complexity of Gluten Sensitivity: Role of Cross-Reactive Antigens and Pathophysiology." Nutrients.</li>
                <li>Stagnaro-Green et al. (2011). "Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy." Thyroid.</li>
                <li>Caturegli et al. (2014). "Hashimoto Thyroiditis: Clinical and Diagnostic Criteria." Autoimmunity Reviews.</li>
                <li>Liontiris & Mazokopakis (2017). "A Concise Review of Hashimoto Thyroiditis and the Role of Genetics, Environmental Factors, and Inositol." Hell J Nucl Med.</li>
                <li>NHANES III Data Series (2002). "Serum TSH, T(4), and Thyroid Antibodies in the United States Population." Journal of Clinical Endocrinology & Metabolism.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy ¬© 2024</p>
            <p class="copyright">Certified Thyroid Health Coach Program | Advanced Clinical Module</p>
        </footer>
    </div>
</body>

</html>